Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We compared ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--with photodynamic therapy with verteporfin in the treatment of predominantly classic neovascular age-related macular degeneration. METHODS: During the first year of this 2-year, multicenter, double-blind study, we randomly assigned patients in a 1:1:1 ratio to receive monthly intravitreal injections of ranibizumab (0.3 mg or 0.5 mg) plus sham verteporfin therapy or monthly sham injections plus active verteporfin therapy. The primary end point was the proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months. RESULTS: Of the 423 patients enrolled, 94.3% of those given 0.3 mg of ranibizumab and 96.4% of those given 0.5 mg lost fewer than 15 letters, as compared with 64.3% of those in the verteporfin group (P<0.001 for each comparison). Visual acuity improved by 15 letters or more in 35.7% of the 0.3-mg group and 40.3% of the 0.5-mg group, as compared with 5.6% of the verteporfin group (P<0.001 for each comparison). Mean visual acuity increased by 8.5 letters in the 0.3-mg group and 11.3 letters in the 0.5-mg group, as compared with a decrease of 9.5 letters in the verteporfin group (P<0.001 for each comparison). Among 140 patients treated with 0.5 mg of ranibizumab, presumed endophthalmitis occurred in 2 patients (1.4%) and serious uveitis in 1 (0.7%). CONCLUSIONS: Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events. Treatment improved visual acuity on average at 1 year. (ClinicalTrials.gov number, NCT00061594 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The MARINA and ANCHOR trials with ranibizumab showed an incidence of 0.05% [30, 31], and a subsequent comparison study of ranibizumab and bevacizumab for neovascular AMD reported rates of 0.16% for ranibizumab and 0.5% for bevacizumab [32].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [31]
In the citing paper
“Ranibizumab anti-Fab immunoreactivity in treatment-naïve patients was between 0–0.9% in the MARINA and ANCHOR trials [30, 31].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [31]
In the citing paper
“However, the requirement for lifelong injections imposes a substantial burden on patients and caregivers, and many patients fail to maintain initial therapeutic benefits owing to noncompliance with the burdensome treatment regimen. 3 , 7 , 8 , 10 , 13 – 20”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [14]
In the citing paper
“In the ANCHOR and MARINA studies, 8-14% of eyes gained 415 letters during months 4 to 12. [22][23][24]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [23]
In the citing paper
“It is now accepted that the best outcomes with anti-VEGF therapies in n-AMD are achieved with regular dosing at specific intervals, usually monthly, as demonstrated in the pivotal trials of ranibizumab, and sometimes two monthly in the first year with aflibercept after the ' three monthly initiation doses'.[22][23][24][25]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [23]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Global data on visual impairment in the year 2002.
(2004) · Europe PMC (PubMed Central) · Cited by 4,157
Some Methods for Strengthening the Common χ 2 Tests
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001616 · Cited by 3,718
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Prevalence of Age-Related Macular Degeneration in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,736
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Age-Related Macular Degeneration and Blindness due to Neovascular Maculopathy
Ferris, F. L., Fine, S. L., & Hyman, L. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040031330019 · Cited by 1,093
Research works printed but not linked: 2
- Resnikoff S, 2004, Bull World Health Organ, 82, 844
- Bressler NM, 2001, Arch Ophthalmol, 119, 198
Cited by
Items 901–1,000 of 1,025
Cystoid Macular Degeneration in Exudative Age-Related Macular Degeneration
Querques, G., Coscas, F., Forte, R., Massamba, N., Sterkers, M., & Souied, E. H. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.01.027 · Cited by 45
“3 mg monthly injected over 24 and 12 onths, respectively.(3,4) The Prospective OCT Imaging of Patients with Neovascular AMD Treated with intraOcular Ranibizumab study demonstrated a variable dosing regimen, mainly based on optical coherence tomography (OCT) findings, to be as effective as a fixed-dosing regimen in imp…”
BackgroundParikh, R., Pirakitikulr, N., Chhablani, J. K., Sakurada, Y., Singh, R. P., & Modi, Y. S. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.08.002 · Cited by 47
Waisbourd, M., Loewenstein, A., Goldstein, M., & Leibovitch, I. (2007) · Drugs & Aging · doi:10.2165/00002512-200724080-00003 · Cited by 48
Intravitreal pegaptanib sodium (Macugen®) for diabetic macular oedema
Querques, G., Bux, A. V., Martinelli, D., Iaculli, C., & Noci, N. D. (2009) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2009.01580.x · Cited by 46
“It was designed to bind all biologically active forms of VEGF and has been used effectively in the treatment of neovascular AMD (Brown et al. 2006; Rosenfeld et al. 2006).”
BackgroundSimcock, P., Kingett, B., Mann, N. S., Reddy, V., & Park, J. (2014) · Eye · doi:10.1038/eye.2014.153 · Cited by 45
Hasler, P. W., Bloch, S. B., Villumsen, J., Fuchs, J., Lund‐Andersen, H., & Larsen, M. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12589 · Cited by 46
“Other potential complications that were systematically monitored included cataract, rhegmatogenous retinal detachment, retinal pigment epithelial tear and vitreous haemorrhage (Brown et al. 2006; Comert et al. 2013).”
BackgroundMethodInfluentialClinical and Histological Aspects of CNV Formation: Studies in an Animal Model
Lassota, N. (2008) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2008.01412.x · Cited by 50
“This improvement happens in about 1 ⁄3 of the treated patients, whereas the majority only experience a halt in disease progression (Brown et al. 2006; Rosenfeld et al. 2006).”
BackgroundInfluentialKwong, T. Q., & Mohamed, M. D. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12371 · Cited by 50
Gianniou, C., Dirani, A., Ferrini, W., Marchionno, L., Decugis, D., Deli, A., Ambresin, A., & Mantel, I. (2014) · Eye · doi:10.1038/eye.2014.258 · Cited by 44
Cha, D. M., Woo, S. J., Kim, H. J., Lee, C., & Park, K. H. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-12730 · Cited by 44
Mason, J. O., Frederick, P. A., Neimkin, M. G., WHITE, M. F., Feist, R. M., Thomley, M. L., & Albert, M. A. (2010) · Retina · doi:10.1097/iae.0b013e3181e09739 · Cited by 44
Ross, A. H., Donachie, P. H. J., Sallam, A. B., STRATTON, I. M., Mohamed, Q. A., Scanlon, P. H., Kirkpatrick, J. N., & Johnston, R. L. (2012) · Eye · doi:10.1038/eye.2012.225 · Cited by 48
Feucht, N., Schönbach, E. M., Lanzl, I. M., Lohmann, C. P., Kotliar, K. E., & Maier, �. (2013) · Clinical ophthalmology · doi:10.2147/opth.s37544 · Cited by 44
Aref, A. A. (2012) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32834ff41d · Cited by 44
“In a recent retrospective case series, Tseng et al. [20 && ] describe 25 eyes of 23 patients who developed a sustained increase in IOP after undergoing a mean of 20.0 (range 8–40) intravitreal injections of bevacizumab and/or ranibizumab for exudative ARMD.”
BackgroundInfluentialAn update on the pharmacotherapy of neovascular age-related macular degeneration
Freund, K. B., Mrejen, S., & Gallego-Pinazo, R. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.787410 · Cited by 44
“3 Current use in ophthalmology While verteporfin PDTmonotherapy is US FDA approved for some forms of neovascular AMD, patients receiving this treatment are more likely to experience further vision loss than those receiving intravitreal anti-VEGF monotherapy [35-37].”
BackgroundKuroda, Y., Yamashiro, K., Tsujikawa, A., Ooto, S., Tamura, H., Oishi, A., Nakanishi, H., Miyake, M., Yoshikawa, M., & Yoshimura, N. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.09.032 · Cited by 45
Lee, J. E., Shin, J. P., Kim, H. W., Chang, W., Kim, Y. C., Lee, S. J., Chung, I. Y., Lee, J. E., VAULT study group, Lee, J. E., et al. (2016) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-016-3489-5 · Cited by 45
“PCV, in replacement of photodynamic therapy (PDT), because it significantly improves vision after monthly intravitreal injections of the agent [3, 4].”
BackgroundAdams, C. M., Anderson, K., Artman, G. D., Bizec, J.-C., Cepeda, R., Elliott, J. M., Fassbender, E. S., Ghosh, M., Hanks, S. M., Hardegger, L. A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01731 · Cited by 46
Eleftheriadou, M. I., Gemenetzi, M. K., Lukić, M., Sivaprasad, S., Hykin, P. G., HAMILTON, R. D., Rajendram, R., Tufail, A., & Patel, P. J. (2018) · Ophthalmology and Therapy · doi:10.1007/s40123-018-0139-5 · Cited by 46
Prefilled syringes for intravitreal drug delivery
Sassalos, T. M., & Paulus, Y. M. (2019) · Clinical ophthalmology · doi:10.2147/opth.s169044 · Cited by 45
Gune, S., Abdelfattah, N. S., Karamat, A., Balasubramanian, S., Marion, K. M., Morgenthien, E. A., & Sadda, S. R. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.030 · Cited by 45
Yafai, Y., Yang, X. M., Niemeyer, M., Nishiwaki, A., Lange, J., Wiedemann, P., King, A. G., Yasukawa, T., & Eichler, W. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.05.016 · Cited by 49
Querques, G., Souied, E. H., & Soubrane, G. (2008) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2008.01226.x · Cited by 44
Self-citationPfister, G., & Savino, W. (2008) · Neuroimmunomodulation · doi:10.1159/000156477 · Cited by 44
INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF RETINAL ANGIOMATOUS PROLIFERATION
Ghazi, N. G., Knape, R. M., Kirk, T. Q., Tiedeman, J. S., & CONWAY, B. P. (2008) · Retina · doi:10.1097/iae.0b013e318162d982 · Cited by 44
Amini, M. A., Karbasi, A., Vahabirad, M., Khanaghaei, M., & Alizamir, A. (2023) · Chonnam Medical Journal · doi:10.4068/cmj.2023.59.3.143 · Cited by 57
“Although the early MARINA 90 and ANCHOR 91 studies declared monthly anti-VEGF therapy was required to preserve vision, the CATT 92 and IVAN 93 trials demonstrated monthly therapy was linked to merely marginally healthier end results compared to aggressive as-needed regimes requiring about eight injections through the…”
MethodBakri, S. J., Couch, S. M., McCannel, C. A., & Edwards, A. O. (2009) · Retina · doi:10.1097/iae.0b013e3181a46a8a · Cited by 43
Amer, R., Priel, E., & Kramer, M. (2015) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-015-2930-5 · Cited by 43
Nanosponge-Mediated Drug Delivery Lowers Intraocular Pressure
Lambert, W. S., Carlson, B. J., van der Ende, A. E., Shih, G. C., Dobish, J. N., Calkins, D. J., & Harth, E. M. (2015) · Translational Vision Science & Technology · doi:10.1167/tvst.4.1.1 · Cited by 43
ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION
Li, A. L., Wykoff, C. C., Wang, R. C., Chen, E., Benz, M. S., Fish, R. H., Wong, T. P., Major, J. C., Brown, D. M., Schefler, A. C., et al. (2015) · Retina · doi:10.1097/iae.0000000000000901 · Cited by 43
Self-citationAvcı, B., Avcı, R., İnan, Ü., & Kaderli, B. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2871 · Cited by 47
Retinal and Choroidal Vascular Diseases: Past, Present, and Future: The 2021 Proctor Lecture
Campochiaro, P. A. (2021) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.62.14.26 · Cited by 46
Zhou, P., Zhang, S., Li, L., Zhang, R., Guo, G., Zhang, Y., Wang, R., Liu, M., Wang, Z., Zhao, H., et al. (2024) · Theranostics · doi:10.7150/thno.98467 · Cited by 46
“Conversely, aflibercept and conbercept, devised as recombinant fusion proteins, function as a “VEGF trap” to capture various forms of VEGF [10,11].”
BackgroundEndophthalmitis following intravitreal injections
Irigoyen, C., Ziahosseini, K., Morphis, G., Stappler, T., & Heimann, H. (2011) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-011-1851-1 · Cited by 45
Querques, G., Bocco, M. C. A., Soubrane, G., & Souied, E. H. (2008) · Acta Ophthalmologica · doi:10.1111/j.1600-0420.2007.01132.x · Cited by 42
“To date, three anti-VEGF drugs are commonly used for treatment of CNV in AMD: bevacizumab; pegaptanib sodium, and ranibizumab.”
BackgroundSelf-citationKachi, S., Binley, K., Yokoi, K., Umeda, N., Akiyama, H., Muramatu, D., Iqball, S., Kan, O., Naylor, S., & Campochiaro, P. A. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.046 · Cited by 41
“A clinical trial has already been completed investigating adenovirus-mediated transfer of the gene encoding pigment epithelium-derived factor in patients with advanced neovascular AMD, and although the results were encouraging in that there was a good safety profile and possible signs of some biological activity (Campo…”
InfluentialKim, Y. J., Sung, K. R., Lee, K. S., Joe, S. G., Lee, J. Y., Kim, J.-G., & Yoon, Y. H. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.02.035 · Cited by 42
“Interestingly, this complication was not noted in randomized clinical trials of novel therapeutics, including anti-VEGF antibody in the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) trial, the Minimally Classic/Occult Trial of the anti-VEGF antibody Ranibi…”
Witkin, A. J., Vuong, L. N., Srinivasan, V. J., Gorczynska, I. M., Reichel, E., Baumal, C. R., Rogers, A. H., Schuman, J. S., Fujimoto, J. G., & Duker, J. S. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.12.018 · Cited by 42
“Two large phase 3 studies, the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) and AntiVEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD (ANCHOR) trials, showed stabilization or improvement of vision in the maj…”
BackgroundKemp, A., Preen, D. B., Morlet, N., Clark, A., McAllister, I. L., Briffa, T. G., Sanfilippo, F. M., Ng, J. Q., McKnight, C. M., Reynolds, W., et al. (2013) · Retina · doi:10.1097/iae.0b013e318276e07b · Cited by 43
“The MARINA(1) and ANCHOR(4,8) Phase III trials investigating the efficacy of VEGF inhibitors for neovascular AMD reported a small trend toward increased arterial thromboembolic events in patients treated with ranibizumab.(1,4,8) In the ANCHOR trial, the incidence of acute MI at 24 months was 2.”
BackgroundTreatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab
Tsujikawa, A., Ooto, S., Yamashiro, K., Tamura, H., Otani, A., & Yoshimura, N. (2010) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-010-0813-1 · Cited by 42
Stemming vision loss with stem cells
Marchetti, V., Krohne, T. U., Friedlander, D. F., & Friedlander, M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42951 · Cited by 44
“Recently introduced VEGF-blocking drugs provide for the first time a therapeutic option to stop disease progression in a sub-set of patients with neovascular AMD, but the effect is only temporary and requires repeated intraocular injections to maintain it (92, 93).”
Shah, A. R., Williams, S. L., Baumal, C. R., ROSNER, B. A., Duker, J. S., & Seddon, J. M. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.11.033 · Cited by 47
“Invest Ophthalmol Vis Sci 1997;38(3):557–568.”
Mizutani, T., Fowler, B. J., Kim, Y., Yasuma, R., Krueger, L. A., Gelfand, B. D., & Ambati, J. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-17440 · Cited by 44
Park, D. H., Sun, H. J., & Lee, S. J. (2016) · International Ophthalmology · doi:10.1007/s10792-016-0391-4 · Cited by 47
Hanemoto, T., Hikichi, Y., Kikuchi, N., & Kozawa, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189035 · Cited by 42
Rosenfeld, P. J., Windsor, M. A., Feuer, W. J., Sun, S. J. J., Frick, K. D., Swanson, E. A., & Huang, D. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.04.008 · Cited by 42
Pipeline therapies for neovascular age related macular degeneration
Arepalli, S., & Kaiser, P. K. (2021) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00325-5 · Cited by 47
“Approved in 2006, it has shown improvement in vision as compared to sham in the MARINA study and to verteporfin ocular photodynamic therapy in predominantly classic lesions in the ANCHOR study [8, 19].”
ResultSelf-citationStatic and dynamic retinal fixation stability in microperimetry
Longhin, E., Convento, E., Pilotto, E., Bonin, G., Vujosevic, S., Kotsafti, O., & Midena, E. (2013) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2013.05.021 · Cited by 42
Ahlers, C., Golbaz, I., Stock, G., Fous, A., Kolar, S., Prünte, C. F., & Schmidt-Erfurth, U. M. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.05.017 · Cited by 43
Takeuchi, T., Hayashi, T., Bedell, M., Zhang, K., Yamada, H., & Tsuneoka, H. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-4497 · Cited by 43
Effect of Bevacizumab on Inflammation and Proliferation in Human Choroidal Neovascularization
Tatar, O., Yoeruek, E., Szurman, P., Bartz-Schmidt, K. U., Adam, A., Shinoda, K., Eckardt, C., Boeyden, V., Claes, C., Pertile, G., et al. (2008) · Archives of Ophthalmology · doi:10.1001/archopht.126.6.782 · Cited by 43
Ruiz-Moreno, J. M., Arias, L., Abraldes, M. J., Montero, J., Udaondo, P., & The RAMDEBURS study group (2021) · International Ophthalmology · doi:10.1007/s10792-021-01906-x · Cited by 41
Meyer, C. H., Mennel, S., & Eter, N. (2007) · Der Ophthalmologe · doi:10.1007/s00347-007-1634-6 · Cited by 41
“Im Protokoll der ANCHOR- und MARINA-Studie war eine postoperative Antibiose von 3 Tagen vorgesehen und der Patient erhielt 3 Tage nach der Injektion einen telefonischen Kontrollanruf [6, 21].”
BackgroundPatel, J. J., Mendes, M., Bounthavong, M., Christopher, M. L. D., Boggie, D. T., & Morreale, A. P. (2010) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2010.01546.x · Cited by 42
Menghini, M., Kloeckener‐Gruissem, B., Fleischhauer, J. C., Kurz-Levin, M. M., Sutter, F. K. P., Berger, W., & Barthelmes, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042014 · Cited by 44
“5] was observed with a median of 4 [3;7] and 10 [7;14] ranibizumab injections during 12 and 24 months, respectively.”
BackgroundInfluentialMariani, A., Deli, A., Ambresin, A., & Mantel, I. (2011) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-011-1734-5 · Cited by 42
Effects of Bevacizumab (Avastin) on Retinal Cells in Organotypic Culture
Kaempf, S., Johnen, S., Salz, A. K., Weinberger, A. W. A., Walter, P., & Thumann, G. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-1265 · Cited by 42
Chong, V. N. (2012) · Ophthalmologica · doi:10.1159/000337152 · Cited by 41
Advances in the management of macular degeneration
Singer, M. A. (2014) · F1000Prime Reports · doi:10.12703/p6-29 · Cited by 43
Moss, J. M., Sanislo, S. R., & Ta, C. N. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.030 · Cited by 41
Regulation of Angiogenesis by Macrophages
Apte, R. S. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-1399-9_2 · Cited by 41
“Currently, a number of treatments directed at exudative AMD and neovascularization from diabetic retinopathy are focused on neutralization of VEGF-A activity in the eye (Brown et al. 2006).”
BackgroundCost-effectiveness of ranibizumab for neovascular age-related macular degeneration
Hurley, S. F., Matthews, J. P., & Guymer, R. H. (2008) · Cost Effectiveness and Resource Allocation · doi:10.1186/1478-7547-6-12 · Cited by 43
“Furthermore, approximately three-quarters of patients with neovascular macular degeneration have the type of disease studied in MARINA (minimally classic or occult choroidal neovascularization) [2,11], compared with one-quarter of patients who have predominantly classic disease [11], which was studied in the ANCHOR tr…”
InfluentialKampougeris, G., Spyropoulos, D., & Mitropoulou, A. (2013) · JOURNAL OF CURRENT GLAUCOMA PRACTICE · doi:10.5005/jp-journals-10008-1132 · Cited by 43
Brandl, C., Breinlich, V., Stark, K. J., Enzinger, S., Aßenmacher, M., Olden, M., Graßmann, F., Graw, J., Heier, M., Peters, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167181 · Cited by 53
Kawashima, Y., Hata, M., Oishi, A., Ooto, S., Yamashiro, K., Tamura, H., Miyata, M., Uji, A., Ueda‐Arakawa, N., & Tsujikawa, A. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.06.015 · Cited by 41
Petrillo, J., Bressler, N. M., Lamoureux, E. L., Ferreira, A., & Cano, S. (2017) · Health and Quality of Life Outcomes · doi:10.1186/s12955-017-0726-5 · Cited by 42
McClintic, S. M., Gao, S. S., Wang, J., Hagag, A. M., Lauer, A. K., Flaxel, C. J., Bhavsar, K. V., Hwang, T. S., Huang, D., Jia, Y., et al. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.01.014 · Cited by 41
Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer
Nakamura, Y. (2021) · Cells · doi:10.3390/cells10071617 · Cited by 44
Borooah, S., Jeganathan, V. S. E., Armbrecht, A. M., Oladiwura, D., Gavin, M., Dhillon, B., & Cackett, P. (2015) · Eye · doi:10.1038/eye.2015.83 · Cited by 42
Tamura, H., Goto, R., Akune, Y., Hiratsuka, Y., Hiragi, S., & Yamada, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133628 · Cited by 44
Shah, A. R., & Priore, L. V. D. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.03.055 · Cited by 42
“Subgroup classification on the basis of fluorescein angiography has been used in numerous trials, including the MPS,(22) TAP,(4) VIP,(23) VISION,(5) MARINA,(6) and AntiVEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration trials.(7) Initially, these s…”
Casten, R. J. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.24 · Cited by 41
Dadgostar, H., & Waheed, N. K. (2008) · Eye · doi:10.1038/eye.2008.86 · Cited by 41
Dong, A., Shen, J., Krause, M., Hackett, S. F., & Campochiaro, P. A. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04839.x · Cited by 44
Pershing, S., Bakri, S. J., & Moshfeghi, D. M. (2013) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20130909-07 · Cited by 42
Berdugo, M., Bejjani, R. A., Valamanesh, F., Savoldelli, M., Jeanny, J., Blanc, D., Ficheux, H., Scherz, A. J., Salomon, Y., BenEzra, D., et al. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0767 · Cited by 41
Quiroz–Mercado, H., Ustariz-Gonzalez, O., Martinez-Castellanos, M. A., Covarrubias, P., Dominguez, F., & Sánchez-Huerta, V. (2007) · Seminars in Ophthalmology · doi:10.1080/08820530701420082 · Cited by 41
Sugino, I. K., Rapista, A., Sun, Q., Wang, J., Nunes, C. F., Cheewatrakoolpong, N., & Zarbin, M. A. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-8400 · Cited by 41
Treatment of age-related macular degeneration: focus on ranibizumab
Spitzer, M. S., Ziemssen, F., Bartz-Schmidt, K. U., Gelişken, F., & Szurman, P. (2008) · Clinical ophthalmology · doi:10.2147/opth.s1959 · Cited by 48
“Monkey experiments demonstrated that the combination of ranibizumab and verteporfi n-PDT reduces leakage from laser-induced CNVs more than PDT alone (Hussain et al 2005).”
Cheung, C. M. G., Yeo, I. Y. S., Li, X., Mathur, R., Lee, S. Y., Chan, C. M., Wong, D., & Wong, T. Y. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.08.002 · Cited by 44
β2–Adrenergic Receptor Antagonism Attenuates CNV Through Inhibition of VEGF and IL-6 Expression
Lavine, J. A., Farnoodian, M., Wang, S., Darjatmoko, S. R., Wright, L. S., Gamm, D. M., Ip, M. S., Sorenson, C. M., & Sheibani, N. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20204 · Cited by 41
Melamud, A., Stinnett, S. S., & Fekrat, S. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.03.014 · Cited by 41
The future of clinical trials of myopia control
Bullimore, M. A., Brennan, N. A., & Flitcroft, I. (2023) · Ophthalmic and Physiological Optics · doi:10.1111/opo.13120 · Cited by 40
“Likewise, the original intravitreal injection of ranibizumab, an anti- vascular endothelial growth factor, was compared with sham injections(31) or verteporfin therapy.(32) Ranibizumab then served as a control in the FDA approval of aflibercept,(33) which in turn was the control in the pivotal clinical trial of broluc…”
BackgroundRecent Insights into the Etiopathogenesis of Diabetic Retinopathy and Its Management
Biswas, A., Choudhury, A. D., Agrawal, S., Bisen, A. C., Sanap, S. N., Verma, S. K., Kumar, M., Mishra, A., Kumar, S., Chauhan, M., et al. (2023) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2023.0068 · Cited by 43
Wykoff, C. C., Garmo, V., Tabano, D. C., Menezes, A., Kim, E., Fevrier, H. B., LaPrise, A., & Leng, T. (2023) · Ophthalmology Science · doi:10.1016/j.xops.2023.100421 · Cited by 49
Iacono, P., Parodi, M. B., Introini, U., Spina, C. L., Varano, M., & Bandello, F. M. (2013) · Retina · doi:10.1097/iae.0b013e3182979e33 · Cited by 40
Ladas, I. D., Kotsolis, A. I., Ladas, D. S., Νισκοπούλου, Μ., Georgalas, I., Papakonstantinou, D., & ROUVAS, A. A. (2010) · Retina · doi:10.1097/iae.0b013e3181d2f11d · Cited by 40
Murakami, Y., Ikeda, Y., Yonemitsu, Y., Miyazaki, M., Inoue, M., Hasegawa, M., Sueishi, K., & Ishibashi, T. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.102 · Cited by 40
“Clinical data analyses have revealed that the intravitreal administration of VEGF-A antagonists such as ranibizumab, bevacizumab, and pegaptanib arrests CNV progression and leakage from CNV, and improves visual acuity (Gragoudas et al., 2004; Avery et al., 2006; Brown et al., 2006; Rosenfeld et al., 2006).”
InfluentialSchmidt-Erfurth, U. M., Wolf, S., & for the PROTECT Study Group (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.135277 · Cited by 40
“Particularly encouraging results were seen in the MARINA and ANCHOR studies,”
ResultBruyère, E., Caillaux, V., Cohen, S. Y., Martiano, D., Orès, R., Puche, N., & Souied, E. H. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.07.004 · Cited by 40
“The development of anti–vascular endothelial growth factor (anti-VEGF) therapy over the last few years has revolutionized the management of exudative age-related macular degeneration (AMD).(2,3) Its use has rapidly been extended to other retinal diseases complicated by CNV.”
BackgroundBarthelmes, D., Campain, A. E., Nguyen, P. V., Arnold, J., McAllister, I. L., Simpson, J. M., Hunyor, A. P., Guymer, R. H., Essex, R. W., Morlet, N., et al. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-308090 · Cited by 45
Cheung, C. M. G., Gan, A. T. L., Fan, Q., Chee, M. L., Apte, R. S., Khor, C. C., Yeo, I. Y. S., Mathur, R., Cheng, C., Wong, T. Y., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m073684 · Cited by 52
Windsor, M. A., Sun, S. J. J., Frick, K. D., Swanson, E. A., Rosenfeld, P. J., & Huang, D. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.09.027 · Cited by 41
Yan, J., Peng, X., Cai, Y., & Cong, W. (2018) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2018.04.033 · Cited by 41
Faatz, H., Farecki, M., Rothaus, K., Gunnemann, F., Gutfleisch, M., Lommatzsch, A. P., & Pauleikhoff, D. (2019) · Eye · doi:10.1038/s41433-019-0429-8 · Cited by 40
You, Q. S., Wang, J., Guo, Y., Flaxel, C. J., Hwang, T. S., Huang, D., Jia, Y., & Bailey, S. T. (2019) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2019.09.004 · Cited by 41
Sharma, S., Khan, M. A., Chaturvedi, A., & RE-ENACT 2 Study Investigators Group (2019) · Ophthalmology and Therapy · doi:10.1007/s40123-019-00228-7 · Cited by 44
BILATERAL EFFECT OF UNILATERAL RANIBIZUMAB IN PATIENTS WITH UVEITIS-RELATED MACULAR EDEMA
Acharya, N. R., Sittivarakul, W., Ying, Q., Hong, K. C., & Lee, S. M. (2011) · Retina · doi:10.1097/iae.0b013e318213da43 · Cited by 40
Tabandeh, H., Chaudhry, N. A., Boyer, D. S., Kon-Jara, V. A., & Flynn, H. W. (2012) · Journal of Cataract & Refractive Surgery · doi:10.1016/j.jcrs.2011.10.036 · Cited by 39
Hanout, M., Ferraz, D., Ansari, M., Maqsood, N., Kherani, S., Sepah, Y. J., Rajagopalan, N., Ibrahim, M., Diana, V., & Nguyen, Q. D. (2013) · BioMed Research International · doi:10.1155/2013/830837 · Cited by 44
“Since the arrival of photodynamic therapy which, for the first time, stabilized vision, there has been significant advances in the treatment of neovascular AMD with the use of VEGF inhibitors [60, 61].”
Background
Metadata
- Authors
- Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S.
- Affiliations
- Houston Methodist (US)
- Cleveland Clinic (US)
- Retina Care Specialists (US)
- Ophthalmic Consultants of Boston (US)
- Genentech (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-10-05
- Volume
- 355
- Issue
- 14
- Pages
- 1432-1444
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2085712747
- Cited by
- 3,522
- References
- 19
- Citations by year
- 2026: 97 · 2025: 110 · 2024: 115 · 2023: 97 · 2022: 117 · 2021: 189 · 2020: 178 · 2019: 140 · 2018: 154 · 2017: 170 · 2016: 188 · 2015: 209 · 2014: 218 · 2013: 247 · 2012: 257
- FWCI
- 161.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- ranibizumab, verteporfin, neovascular age-related macular degeneration, anti-VEGF therapy, photodynamic therapy, intravitreal injection, visual acuity, endophthalmitis, uveitis
- MeSH terms
- Ranibizumab, Verteporfin, Aged, Aged, 80 and over, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Injections, Macular Degeneration, Male, Middle Aged, Photochemotherapy, Porphyrins, Visual Acuity, Photosensitizing Agents, Choroidal Neovascularization, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.